Clinical-stage biotechnology company focused on research, development and commercialization of novel psychedelic pharmaceuticals PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) announced having received a Ketamine patent by the United States Patent and Trademark Office (USPTO) titled ‘Method and Composition for Decreasing the Psychotomimetic Side Effect and Addictive Disorder of Ketamine.’
The patent was allocated U.S. Patent No. 11,213,495 and it refers to the combination formulation of Food and Drug Administration (FDA) approved ketamine and betaine anhydrous (KETABET) which according to a clinical study has confirmed to enhance the antidepressant effect while potentially reducing the negative side effects of ketamine drastically.
This patent strengthens the company’s global patent portfolio, additionally, it also provides a wide potential of KETABET use in various mental health, novel delivery forms, neurological and pain disorders including PharmaTher’s patented hydrogen-forming microneedle patch delivery systems.
“We are extremely pleased about the grant of this patent in the U.S. as it further validates the potential of KETABET™, strengthens our intellectual property position, and highlights our commitment to innovation of ketamine for mental health, neurological and pain disorders,” said the company’s CEO, Fabio Chianelli.
The outcome from the ongoing studies will determine if PharmaTher will advance the KETABET program with its microneedle patch technology during the phase 2 clinical studies.